Liver Disease
Conference Coverage
Oral SGLT-2 inhibitor reduced liver fat in diabetics with NAFLD
When it comes to type 2 diabetes and NAFLD, a new drug may kill two birds with one stone.
Conference Coverage
Switching to tenofovir alafenamide may benefit HBV patients
PHILADELPHIA – It has similar efficacy to tenofovir disoproxil, with fewer bone and renal effects, according to results of two large international...
From the Journals
Red meat intake linked to NAFLD risk
Higher dietary intake of red and processed meats is linked to an increased risk of nonalcoholic fatty liver disease and insulin resistance.
Conference Coverage
Pre-screening could help identify NAFLD biopsy candidates
PHILADELPHIA – Metabolic syndrome and liver stiffness measured by VCTE or MRE are among the criteria that can be used for at-risk patients.
From the Journals
Bioengineered liver models screen drugs and study liver injury
Advances in bioengineered livers will show improving sensitivity for the prediction of clinically relevant drug and disease outcomes.
From the Journals
Tenofovir didn’t prevent hepatitis B transmission to newborns
The maternal HBV transmission rate was unexpectedly low in both the placebo and active groups.
From the Journals
HCV infection tied to premature ovarian senescence and a high miscarriage rate
Infertility and adverse pregnancy outcomes in HCV-infected women appear associated with increased ovarian senescence.
From the Journals
Racial disparities by region persist despite multiple liver transplant allocation schemes
Disparities with African Americans have improved, but new disparities with Hispanics and Asians have developed.
From the AGA Journals
Engineered liver models to study human hepatotropic pathogens
2-D and 3-D cell cultures and humanized rodent models are be used and further developed.
From the Journals
Sofosbuvir/ledipasvir looks good in HBV coinfected patients
Was there HBV reactivation with treatment?